The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Tempus AI TEM jumped 7.3% at yesterday’s close after securing FDA 510(k) clearance for its ECG-Low EF software, its second ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled "Cardio-microcurrent Device ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

Given the current trends, heart failure with normal ejection fraction will become the most common form of heart failure, for which we do not currently have an evidence-based successful treatment.

The US Food and Drug Administration (FDA) has granted 510 (k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software. This software utilises AI to detect individuals with a low left ...

There are consistent associations between elevated urinary metal levels and increased HF risk over time across geographically diverse cohorts of adults.